Список литературы

Поставить закладку

Higgins R.D. et al. Bronchopulmonary Dysplasia: Executive Summary of a Workshop // J. Pediatr. 2018. Vol. 197. P. 300–308.
Wang S.H., Tsao P.N. Phenotypes of bronchopulmonary dysplasia // International Journal of Molecular Sciences. MDPI AG, 2020. Vol. 21, № 17. P. 1–20.
Thébaud B. et al. Bronchopulmonary dysplasia // Nature Reviews Disease Primers. Nature Publishing Group, 2019. Vol. 5, № 1.
Ашерова И. К., Бабак О. А., Богданова А. В. [и др.]. Бронхолегочная Дисплазия. Москва: (РУДН), Российский университет дружбы народов, 2020. 176с p.
Jobe A.H. Animal models, learning lessons to prevent and treat neonatal chronic lung disease // Front. Med. 2015. Vol. 2, № AUG. P. 1–13.
Husain A.N., Siddiqui N.H., Stocker J.T. Pathology of arrested acinar development in postsurfactant bronchopulmonary dysplasia // Hum. Pathol. 1998. Vol. 29, № 7. P. 710–717.
Coalson J.J. Pathology of new bronchopulmonary dysplasia // Semin. Neonatol. 2003. Vol. 8, № 1. P. 73–81.
Ambalavanan N. et al. Predictors of death or bronchopulmonary dysplasia in preterm infants with respiratory failure // J. Perinatol. 2008. Vol. 28, № 6. P. 420–426.
Lemons J.A. et al. Very Low Birth Weight Outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1995 Through December 1996 // Pediatrics. 2001. Vol. 107, № 1. P. e1–e1.
Marshall D.D. et al. Risk factors for chronic lung disease in the surfactant era: A North Carolina population-based study of very low birth weight infants // Pediatrics. 1999. Vol. 104, № 6. P. 1345–1350.
Oh W. et al. Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants // J. Pediatr. 2005. Vol. 147, № 6. P. 786–790.
Rojas M.A. et al. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease // J. Pediatr. 1995. Vol. 126, № 4. P. 605–610.
Stoll B.J. et al. Trends in care practices, morbidity, and mortality of extremely preterm Neonates, 1993-2012 // JAMA - J. Am. Med. Assoc. 2015. Vol. 314, № 10. P. 1039–1051.
Young T.E. et al. Population-based Study of Chronic Lung Disease in Very Low Birth Weight Infants in North Carolina in 1994 With Comparisons With 1984 // Pediatrics. 1999. Vol. 104, № 2. P. e17–e17.
Younge N. et al. Survival and Neurodevelopmental Outcomes among Periviable Infants // N. Engl. J. Med. 2017. Vol. 376, № 7. P. 617–628.
Walsh M.C. et al. Impact of a physiologic definition on bronchopulmonary dysplasia rates // Pediatrics. 2004. Vol. 114, № 5. P. 1305–1311.
Bose C. et al. Fetal growth restriction and chronic lung disease among infants born before the 28th week of gestation // Pediatrics. 2009. Vol. 124, № 3. P. e450–e45.
McEvoy C.T., Spindel E.R. Pulmonary Effects of Maternal Smoking on the Fetus and Child: Effects on Lung Development, Respiratory Morbidities, and Life Long Lung Health // Paediatr. Respir. Rev. Elsevier Ltd, 2017. Vol. 21. P. 27–33.
Morrow L.A. et al. Antenatal determinants of bronchopulmonary dysplasia and late respiratory disease in preterm infants // Am. J. Respir. Crit. Care Med. 2017. Vol. 196, № 3. P. 364–374.
Ryan S.W., Nycyk J., Shaw B.N.J. Prediction of chronic neonatal lung disease on day 4 of life // Eur. J. Pediatr. 1996. Vol. 155, № 8. P. 668–671.
Lavoie P.M., Pham C., Jang K.L. Heritability of bronchopulmonary dysplasia, defined according to the consensus statement of the national institutes of health // Pediatrics. 2008. Vol. 122, № 3. P. 479–485.
Parker R.A., Lindstrom D.P., Cotton R.B. Evidence from twin study implies possible genetic susceptibility to bronchopulmonary dysplasia // Semin. Perinatol. 1996. Vol. 20, № 3. P. 206–209.
Bhandari V. et al. Genetics of bronchopulmonary dysplasia: When things do not match up, it is only the beginning // J. Pediatr. 2019. Vol. 208. P. 298–299.
Lal C.V., Bhandari V., Ambalavanan N. Genomics, microbiomics, proteomics, and metabolomics in bronchopulmonary dysplasia // Semin. Perinatol. Elsevier Inc., 2018. Vol. 42, № 7. P. 425–431.
Parad R.B. et al. Role of Genetic Susceptibility in the Development of Bronchopulmonary Dysplasia // J. Pediatr. Elsevier Inc., 2018. Vol. 203. P. 234-241.e2.
Torgerson D.G. et al. Ancestry and genetic associations with bronchopulmonary dysplasia in preterm infants // Am. J. Physiol. - Lung Cell. Mol. Physiol. 2018. Vol. 315, № 5. P. L858–L869.
Yu K.H. et al. The genetic predisposition to bronchopulmonary dysplasia // Curr. Opin. Pediatr. 2016. Vol. 28, № 3. P. 318–323.
Bonadies L. et al. Present and future of bronchopulmonary dysplasia // J. Clin. Med. 2020. Vol. 9, № 5. P. 1–26.
Kim S.H. et al. Effect of antenatal azithromycin for Ureaplasma spp. on neonatal outcome at ≤30 weeks’ gestational age // Pediatr. Int. 2019. Vol. 61, № 1. P. 58–62.
Dassios T. et al. Duration of mechanical ventilation and prediction of bronchopulmonary dysplasia and home oxygen in extremely preterm infants // Acta Paediatr. Int. J. Paediatr. 2021. Vol. 110, № 7. P. 2052–2058.
Овсянников Дмитрий Юрьевич, Кравчук Дарья Андреевна Н.Д.Ю. Клиническая патофизиология органов дыхания недоношенных детей // Неонатология: новости, мнения, обучение. 2018. Vol. 3, № 21. P. 74–98.
Kalikkot Thekkeveedu R., Guaman M.C., Shivanna B. Bronchopulmonary dysplasia: A review of pathogenesis and pathophysiology // Respir. Med. 2017. Vol. 132, № August. P. 170–177.
Jobe A.H. Mechanisms of Lung Injury and Bronchopulmonary Dysplasia // Am. J. Perinatol. 2016. Vol. 33, № 11. P. 1076–1078.
Thibeault D.W. et al. Lung Elastic Tissue Maturation and Perturbations During the Evolution of Chronic Lung Disease // Pediatrics. 2000. Vol. 106, № 6. P. 1452–1459.
Berkelhamer S.K., Mestan K.K., Steinhorn R. An update on the diagnosis and management of bronchopulmonary dysplasia (BPD)-associated pulmonary hypertension // Semin. Perinatol. Elsevier Inc., 2018. Vol. 42, № 7. P. 432–443.
Chaw P.S. et al. Respiratory syncytial virus-associated acute lower respiratory infections in children with bronchopulmonary dysplasia: Systematic review and meta-analysis // J. Infect. Dis. 2021. Vol. 222, № Suppl 7. P. S620–S627.
Lal C.V., Ambalavanan N. Genetic predisposition to bronchopulmonary dysplasia // Semin. Perinatol. Elsevier, 2015. Vol. 39, № 8. P. 584–591.
Hamvas A. et al. Exome sequencing identifies gene variants and networks associated with extreme respiratory outcomes following preterm birth // BMC Genet. BMC Genetics, 2018. Vol. 19, № 1. P. 1–10.
Gao J. et al. CD74, a novel predictor for bronchopulmonary dysplasia in preterm infants // Medicine (Baltimore). 2020. Vol. 99, № 48. P. e23477.
Leong M. Genetic approaches to bronchopulmonary dysplasia // Neoreviews. 2019. Vol. 20, № 5. P. e272–e279.
Бондарь В.А. , Давыдова И.В. , Басаргина М.А. , Фисенко А.П. , Пушков А.А. , Жани И.С. , Борисов И.В. С.К.В. Роль Генетических Предикторов В Доклинической Диагностике Бронхолегочной Дисплазии // Кремлевская Медицина. Клинический Вестник. 2022. Vol. 1. P. 5–9.
Trittmann J.K. et al. Arginase and α-smooth muscle actin induction after hyperoxic exposure in a mouse model of bronchopulmonary dysplasia. // Clin Exp Pharmacol Physiol. 2018. Vol. 45, № 6. P. 556–562.
Abed N.T. et al. Relation of asymmetric dimethylarginine with pulmonary morbidities in neonatal respiratory distress syndrome // J. Neonatal. Perinatal. Med. 2021. Vol. 14, № 4. P. 511–517.
Nuytten A. et al. Postnatal Corticosteroids Policy for Very Preterm Infants and Bronchopulmonary Dysplasia // Neonatology. 2020. Vol. 117, № 3. P. 308–315.
McEvoy C.T. et al. Bronchopulmonary dysplasia: NHLBI Workshop on the primary prevention of chronic lung diseases // Ann. Am. Thorac. Soc. 2014. Vol. 11, № SUPPL. 3.
Stoll B.J. et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network // Pediatrics. 2010. Vol. 126, № 3. P. 443–456.
Jobe A., Bancalari E. Bronchopulmonary Dysplasia // Am. J. Respir. Crit. Care Med. 2001. Vol. 163. P. 1723–1729.
Баранов A.A. et al. Ведение детей с бронхолегочной дисплазией // Педиатрическая фармакология. 2016. Vol. 13, № 4. P. 319–333.
Sweet D.G. et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2019 Update // Neonatology. 2019. Vol. 115, № 4. P. 432–450.
Voynow J. “New” bronchopulmonary dysplasia and chronic lung disease // Paediatr. Respir. Rev. 2017. Vol. 24. P. 17–18.
Shalish W. et al. The Impact of Time Interval between Extubation and Reintubation on Death or Bronchopulmonary Dysplasia in Extremely Preterm Infants // J. Pediatr. Elsevier Inc., 2019. Vol. 205. P. 70-76.e2.
Soliman N. et al. Preeclampsia and the Risk of Bronchopulmonary Dysplasia in Preterm Infants Less Than 32 Weeks’ Gestation // Am. J. Perinatol. 2017. Vol. 34, № 6. P. 585–592.
Mirza H. et al. Duration of significant patent ductus arteriosus and bronchopulmonary dysplasia in extremely preterm infants // J. Perinatol. Springer US, 2019. Vol. 39, № 12. P. 1648–1655.
Jung E., Lee B. Late-Onset Sepsis as a Risk Factor for Bronchopulmonary Dysplasia in Extremely Low Birth Weight Infants: A Nationwide Cohort Study // Sci. Rep. 2019. Vol. 9, № 1. P. 1–7.
Kim S.H. et al. Risk factors that affect the degree of bronchopulmonary dysplasia: Comparison by severity in the same gestational age // PLoS One. 2020. Vol. 15, № 7. P. 1–12.
Patel R.M. et al. Enteral iron supplementation, red blood cell transfusion, and risk of bronchopulmonary dysplasia in very-low-birth-weight infants // Transfusion. 2019. Vol. 59, № 5. P. 1675–1682.
Chen X. et al. Neonatal hematological parameters and the risk of moderate-severe bronchopulmonary dysplasia in extremely premature infants // BMC Pediatr. BMC Pediatrics, 2019. Vol. 19, № 1. P. 1–7.
Yen J.M. et al. Eosinophilia in very low birth weight infants // Pediatr. Neonatol. Taiwan Pediatric Association, 2010. Vol. 51, № 2. P. 116–123.
Kurata H. et al. Inflammation in the neonatal period and intrauterine growth restriction aggravate bronchopulmonary dysplasia // Pediatr. Neonatol. Elsevier Taiwan LLC, 2019. Vol. 60, № 5. P. 496–503.
Klevebro S. et al. Early energy and protein intakes and associations with growth, BPD, and ROP in extremely preterm infants // Clin. Nutr. 2019. Vol. 38, № 3. P. 1289–1295.
Chen C. et al. Low-Dose Vitamin D Protects Hyperoxia-Induced Bronchopulmonary Dysplasia by Inhibiting Neutrophil Extracellular Traps // Front. Pediatr. 2020. Vol. 8, № July. P. 1–10.
Greenough A. et al. A simple chest radiograph score to predict chronic lung disease in prematurely born infants // Br. J. Radiol. 1999. Vol. 72, № JUN. P. 530–533.
Starr M.C. et al. Acute Kidney Injury and Bronchopulmonary Dysplasia in Premature Neonates Born Less than 32 Weeks’ Gestation // Am J Perinatol. 2020. Vol. 37, № 3. P. 341–348.
Gao Y. et al. Risk prediction of bronchopulmonary dysplasia in preterm infants by the nomogram model // Front. Pediatr. 2023. Vol. 11, № March. P. 1–11.
Rocha G., Ribeiro O., Guimarães H. Fluid and electrolyte balance during the first week of life and risk of bronchopulmonary dysplasia in the preterm neonate // Clinics. CLINICS, 2010. Vol. 65, № 7. P. 663–674.
Duijts L. et al. European Respiratory Society guideline on long-term management of children with bronchopulmonary dysplasia // Eur. Respir. J. European Respiratory Society, 2020. Vol. 55, № 1.
Sriram S. et al. Early Blood Gas Predictors of Bronchopulmonary Dysplasia in Extremely Low Gestational Age Newborns // Int. J. Pediatr. 2014. Vol. 2014. P. 1–8.
Rodríguez-Blanco S. et al. N-terminal-probrain natriuretic peptide as a biomarker of moderate to severe bronchopulmonary dysplasia in preterm infants: A prospective observational study // Pediatr. Pulmonol. 2018. Vol. 53, № 8. P. 1073–1081.
Zhou L. et al. N-terminal pro-B-type natriuretic peptide as a biomarker of bronchopulmonary dysplasia or death in preterm infants: A retrospective cohort analysis // Front. Pediatr. 2019. Vol. 7, № APR. P. 1–7.
Hansmann G. et al. Pulmonary hypertension in bronchopulmonary dysplasia // Pediatr. Res. Springer US, 2021. Vol. 89, № 3. P. 446–455.
Xiong T. et al. Natriuretic peptides in bronchopulmonary dysplasia: a systematic review // J. Perinatol. Springer US, 2020. Vol. 40, № 4. P. 607–615.
Е. Г. Фурман, Д. Ю. Овсянников И.В.Д. и др. Функциональная диагностика и клиническая респираторная патофизиология бронхолегочной дисплазии: от младенцев до взрослых : монография. Пермь: Издательство Пермского национального исследовательского политехнического университета, 2020. 165 p.
Kulkarni G. et al. Polysomnography for the management of oxygen supplementation therapy in infants with chronic lung disease of prematurity // J. Matern. Neonatal Med. Informa UK Ltd., 2019. Vol. 32, № 21. P. 3640–3646.
Dassios T. et al. Correlation of radiographic thoracic area and oxygenation impairment in bronchopulmonary dysplasia // Respir. Physiol. Neurobiol. Elsevier B.V., 2016. Vol. 220, № September. P. 40–45.
Hyödynmaa E. et al. Frequency and clinical correlates of radiographic patterns of bronchopulmonary dysplasia in very low birth weight infants by term age // Eur. J. Pediatr. 2012. Vol. 171, № 1. P. 95–102.
Sung T.J. et al. Relationship between clinical severity of “new” bronchopulmonary dysplasia and HRCT abnormalities in VLBW infants // Pediatr. Pulmonol. 2018. Vol. 53, № 10. P. 1391–1398.
Mahut B. et al. Chest computed tomography findings in bronchopulmonary dysplasia and correlation with lung function // Arch. Dis. Child. Fetal Neonatal Ed. 2007. Vol. 92, № 6. P. 459–464.
Hansmann G. et al. 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT // Journal of Heart and Lung Transplantation. Elsevier USA, 2019. Vol. 38, № 9. P. 879–901.
Bokiniec R. et al. Echocardiographic evaluation of right ventricular function in preterm infants with bronchopulmonary dysplasia // Echocardiography. 2017. Vol. 34, № 4. P. 577–586.
Bokiniec R. et al. Evaluation of left ventricular function in preterm infants with bronchopulmonary dysplasia using various echocardiographic techniques // Echocardiography. 2017. Vol. 34, № 4. P. 567–576.
Van Loon R. et al. Pediatric pulmonary hypertension in the Netherlands: Epidemiology and characterization during the period 1991 to 2005 // Circulation. 2011. Vol. 124, № 16. P. 1755–1764.
Siassi B. et al. Practical neonatal echocardiography. 2019. 304 p.
Krishnan U. et al. Evaluation and Management of Pulmonary Hypertension in Children with Bronchopulmonary Dysplasia // J. Pediatr. 2017. Vol. 188. P. 24-34.e1.
Mohamed A. et al. Lung Ultrasound for Prediction of Bronchopulmonary Dysplasia in Extreme Preterm Neonates: A Prospective Diagnostic Cohort Study // J. Pediatr. Elsevier Inc, 2021. Vol. 238. P. 187-192.e2.
Liu X. et al. Lung ultrasound predicts the development of bronchopulmonary dysplasia: a prospective observational diagnostic accuracy study // Eur. J. Pediatr. European Journal of Pediatrics, 2021. Vol. 180, № 9. P. 2781–2789.
Radulova P. et al. Lung ultrasound in premature infants as an early predictor of bronchopulmonary dysplasia // J. Clin. Ultrasound. 2022. Vol. 50, № 9. P. 1322–1327.
Aldecoa-Bilbao V, Velilla M, Teresa-Palacio M et al. Lung Ultrasound in Bronchopulmonary Dysplasia: Patterns and Predictors in Very Preterm Infants. // Neonatology. 2021. Vol. 118, № 5. P. 537-545.
Alonso-Ojembarrena A. et al. The Predictive Value of Lung Ultrasound Scores in Developing Bronchopulmonary Dysplasia: A Prospective Multicenter Diagnostic Accuracy Study // Chest. Elsevier Inc., 2021. Vol. 160, № 3. P. 1006–1016.
Loi B. et al. Lung ultrasound to monitor extremely preterm infants and predict bronchopulmonary dysplasia a multicenter longitudinal cohort study // Am. J. Respir. Crit. Care Med. 2021. Vol. 203, № 11. P. 1398–1409.
Pezza L. et al. Meta-Analysis of Lung Ultrasound Scores for Early Prediction of Bronchopulmonary Dysplasia // Ann. Am. Thorac. Soc. 2022. Vol. 19, № 4. P. 659–667.
Oulego-Erroz I. et al. Early assessment of lung aeration using an ultrasound score as a biomarker of developing bronchopulmonary dysplasia: a prospective observational study // J. Perinatol. Springer Nature, 2021. Vol. 41, № 1. P. 62–68.
Singh Y. et al. International evidence-based guidelines on Point of Care Ultrasound ( POCUS ) for critically ill neonates and children issued by the POCUS Working Group of the European Society of Paediatric and Neonatal Intensive Care ( ESPNIC ) // Crit Care. Critical Care, 2020. Vol. 24, № 1. P. 1–16.
Brat R, Yousef N, Klifa R, Reynaud S, Shankar Aguilera S D.L.D. Lung Ultrasonography Score to Evaluate Oxygenation and Surfactant Need in Neonates Treated With Continuous Positive Airway Pressure. // JAMA Pediatr. 2015. Vol. 169, № 8. P. e151797.
Sun Y.H. et al. A modified lung ultrasound score to evaluate short-term clinical outcomes of bronchopulmonary dysplasia // BMC Pulm. Med. 2022. Vol. 22, № 1. P. 1–11.
Павлинова Е. Б., Оксеньчук Т. В. К.Л.А. Применение бронхофонографического исследования для оценки дыхательных расстройств у недоношенных детей с респираторным дистресс-синдромом // Бюллетень сибирской медицины. 2010. Vol. 9, № 3. P. 125–130.
Павлинова Е.Б. et al. Бронхофонография – новый метод диагностики и прогнозирования бронхолегочной дисплазии // Вестник СурГУ. Медицина. 2012. Vol. 3, № 13. P. 15–23.
Askie L.M. et al. Effects of targeting lower versus higher arterial oxygen saturations on death or disability in preterm infants // Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd, 2017. Vol. 2017, № 4.
Tae-Jung S. Bronchopulmonary dysplasia: How can we improve its outcomes? // Korean J. Pediatr. 2019. Vol. 62, № 10. P. 367–373.
Овсянников Д. Ю. , Болибок А. М. , Кршеминская И. В. Е.А.Д. Доказательная пульмонология новорожденных и грудных детей: учебное пособие. РУДН. Москва, 2017. 168 p.
Askie LM, Henderson-Smart DJ, Irwig L S.J. Oxygen-saturation targets and outcomes in extremely preterm infants. // N Engl J Med. 2003. Vol. 349, № 10. P. 959–967.
De Pieri C., Amaddeo A., Fauroux B. About the role of polysomnography in weaning and titration of home oxygen therapy in children with bronchopulmonary dysplasia // J Matern Fetal Neonatal Med. 2020. Vol. 33, № 5. P. 875.
Isayama T. et al. Association of noninvasiveventilation strategies withmortality and bronchopulmonarydysplasiaamong preterm infants: A systematic review and meta-analysis // JAMA - J. Am. Med. Assoc. 2016. Vol. 316, № 6. P. 611–624.
Thome U.H., Ambalavanan N. Permissive hypercapnia to decrease lung injury in ventilated preterm neonates // Semin. Fetal Neonatal Med. 2009. Vol. 14, № 1. P. 21–27.
Thome U.H. et al. Permissive hypercapnia in extremely low birthweight infants (PHELBI): A randomised controlled multicentre trial // Lancet Respir. Med. 2015. Vol. 3, № 7. P. 534–543.
Ambalavanan N., Carlo W.A. Ventilatory Strategies in the Prevention and Management of Bronchopulmonary Dysplasia // Semin. Perinatol. 2006. Vol. 30, № 4. P. 192–199.
Rhein L. et al. Transmitted home oximetry and duration of home oxygen in premature infants // Pediatrics. 2020. Vol. 146, № 2.
Савва Н.Н., Овсянников Д.Ю. и др. Тяжелая бронхолегочная дисплазия:медицинское сопровождение на дому. Москва: Издательство: Проспект, 2020. 120 p.
Primhak R. Oxygen titration strategies in chronic neonatal lung disease // Paediatr. Respir. Rev. Elsevier Ltd, 2010. Vol. 11, № 3. P. 154–157.
Filippone M. et al. Update on Postnatal Corticosteroids to Prevent or Treat Bronchopulmonary Dysplasia // Am. J. Perinatol. 2019. Vol. 36. P. S58–S62.
Shinwell E.S. et al. Inhaled corticosteroids for bronchopulmonary dysplasia: A meta-analysis // Pediatrics. American Academy of Pediatrics, 2016. Vol. 138, № 6.
Abman S. et al. Interdisciplinary Care of Children with Severe Bronchopulmonary Dysplasia // J. Pediatr. Elsevier Inc., 2017. Vol. 181. P. 12-28.e1.
Gien J. et al. Retrospective Analysis of an Interdisciplinary Ventilator Care Program Intervention on Survival of Infants with Ventilator-Dependent Bronchopulmonary Dysplasia // Am. J. Perinatol. 2017. Vol. 34, № 2. P. 155–163.
Cuna A. et al. Effectiveness and safety of repeat dexamethasone for bronchopulmonary dysplasia // J. Perinatol. Springer US, 2021. Vol. 41, № 8. P. 1956–1962.
Doyle L.W. et al. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: A multicenter, international, randomized, controlled trial // Pediatrics. 2006. Vol. 117, № 1. P. 75–83.
Cuna A. et al. A comparison of 7-day versus 10-day course of low-dose dexamethasone for chronically ventilated preterm infants // J. Perinatol. Nature Publishing Group, 2017. Vol. 37, № 3. P. 301–305.
Ng G., da Silva O., Ohlsson A. Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants // Cochrane Database Syst. Rev. 2016. Vol. 12, № 12.
Овсянников Д.Ю., Бойцова Е.В., Жесткова М.А., Кршеминская И.В., Ашерова И.К., Украинцев С.Е. и др. Неонатальная пульмонология / ed. под ред Д.Ю. Овсянникова. Москва, 2022. 168 p.
Овсянников Д.Ю. Небулайзерная терапия у новорожденных детей // Пульмонология и аллергология. 2012. Vol. 2. P. 7–10.
Mandell E.W., Kratimenos P., Abman S.H. S.R.H. Drugs for the Prevention and Treatment of Bronchopulmonary Dysplasia // Clin Perinatol. 2019. Vol. 46, № 2. P. 291–310.
Овсянников Д.Ю. Ингаляционная терапия у новорожденных детей // Эффективная фармакотерапия. 2010. Vol. 23. P. 6–8.
Brundage KL, Mohsini KG, Froese AB F.J. Bronchodilator response to ipratropium bromide in infants with bronchopulmonary dysplasia. // Am Rev Respir Dis. 1990. Vol. 142, № 5. P. 1137–4.
Greenberg R.G. et al. Furosemide Exposure and Prevention of Bronchopulmonary Dysplasia in Premature Infants // J. Pediatr. Elsevier Inc., 2019. Vol. 208. P. 134-140.e2.
Narayan O. et al. Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK // J. Med. Econ. Taylor and Francis Ltd., 2020. Vol. 23, № 12. P. 1640–1652.
Vesoulis Z. et al. Early High-Dose Caffeine Increases Seizure Burden in Extremely Preterm Neonates: A Preliminary Study // J. Caffeine Res. 2016. Vol. 6, № 3. P. 101–107.
Doyle L.W., Ranganathan S., Cheong J.L.Y. Neonatal caffeine treatment and respiratory function at 11 years in children under 1, 251 g at Birth // Am. J. Respir. Crit. Care Med. 2017. Vol. 196, № 10. P. 1318–1324.
Schmidt B. et al. Academic performance, motor function, and behavior 11 years after neonatal caffeine citrate therapy for apnea of prematurity: An 11-year follow-up of the CAP randomized clinical trial // JAMA Pediatr. 2017. Vol. 171, № 6. P. 564–572.
Al-Jebawi Y. et al. Low caloric intake and high fluid intake during the first week of life are associated with the severity of bronchopulmonary dysplasia in extremely low birth weight infants // J. Neonatal. Perinatal. Med. IOS Press, 2020. Vol. 13, № 2. P. 207–214.
Kim L., McGrath-Morrow S., Collaco J. Impact of breast milk on respiratory outcomes in infants with bronchopulmonary dysplasia // Pediatr. Pulmonol. 2019. Vol. 54, № 3. P. 313–318.
Miller J. et al. A systematic review and meta-analysis of human milk feeding and morbidity in very low birth weight infants // Nutrients. 2018. Vol. 10, № 6. P. 1–35.
Villamor-Martínez E. et al. Donor human milk protects against bronchopulmonary dysplasia: A systematic review and meta-analysis // Nutrients. 2018. Vol. 10, № 2. P. 9–15.
Villamor-Martínez E. et al. Mother’s own milk and bronchopulmonary dysplasia: A systematic review and meta-analysis // Front. Pediatr. 2019. Vol. 7, № JUN. P. 1–9.
Huang J. et al. Human milk as a protective factor for bronchopulmonary dysplasia: A systematic review and meta-analysis // Arch. Dis. Child. Fetal Neonatal Ed. 2019. Vol. 104, № 2. P. F128–F136.
Schanler R.J. et al. Randomized trial of donor human milk versus preterm formula as substitutes for mothers’ own milk in the feeding of extremely premature infants // Pediatrics. 2005. Vol. 116, № 2. P. 400–406.
Abiramalatha T., Ramaswamy VV, Bandyopadhyay T, Somanath SH, Shaik NB, Pullattayil AK W.G. Interventions to Prevent Bronchopulmonary Dysplasia in Preterm Neonates: An Umbrella Review of Systematic Reviews and Meta-analyses. // JAMA Pediatr. 2022. Vol. 176, № 5. P. 502-516.
Jensen E.. et al. Determinants of severe metabolic bone disease in very low-birth-weight infants with severe bronchopulmonary dysplasia admitted to a tertiary referral center // Am. J. Perinatol. Thieme Medical Publishers, 2016. Vol. 2, № 01. P. 107–113.
Alverson D., Isken V., Cohen R. Effect of booster blood transfusions on oxygen utilization in infants with bronchopulmonary dysplasia // J. Pediatr. 1988. Vol. 113, № 4. P. 722–726.
Gibson BE, Todd A, Roberts I, Pamphilon D, Rodeck C, Bolton-Maggs P, Burbin G, Duguid J, Boulton F, Cohen H, Smith N, McClelland DB, Rowley M T.G. Transfusion guidelines for neonates and older children // Br. J. Haematol. 2004. Vol. 124, № 4. P. 433–453.
Bancalari E., Wilson-Costello D., Iben S. Management of infants with bronchopulmonary dysplasia in North America // Early Hum. Dev. 2005. Vol. 81, № 2. P. 171–179.
Baraldi E. et al. Home oxygen therapy in infants with bronchopulmonary dysplasia: A prospective study // Eur. J. Pediatr. 1997. Vol. 156, № 11. P. 878–882.
Mourani P.M. et al. Effects of Long-Term Sildenafil Treatment for Pulmonary Hypertension in Infants with Chronic Lung Disease // J. Pediatr. 2009. Vol. 154, № 3.
Alghamdi M.H. et al. Primary pulmonary arterial hypertension and autoimmune polyendocrine syndrome in a pediatric patient // Pediatr. Cardiol. 2010. Vol. 31, № 6. P. 872–874.
Sun L. et al. Clinical Efficacy and Safety of Different Doses of Sildenafil in the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Network Meta-analysis // Front. Pharmacol. 2021. Vol. 12, № September. P. 1–10.
Cookson M.W. et al. Pulmonary vasodilator strategies in neonates with acute hypoxemic respiratory failure and pulmonary hypertension // Semin. Fetal Neonatal Med. Elsevier Ltd, 2022. Vol. 27, № 4. P. 101367.
Буров А.А. Терапия оксидом азота в неонатологии // Неонатология: новости, мнения, обучение. 2014. Vol. 4, № 6. P. 73–86.
Panitch H.B. 21 - Children Dependent on Respiratory Technolog // Kendig’s Disorders of the Respiratory Tract in Children. Ninth Edit / ed. Wilmott R.W. et al. Philadelphia: Elsevier, 2019. P. 382–394.
Акоев Ю. С. и др. Диагностика и комплексная реабилитация перинатальной патологии новорожденных: руководство для педиатров, неонатологов, детских невропатологов и врачей ЛФК. Москва: ПедиатрЪ, 2012. 155 p.
Конова О.М. et al. Часто болеющие дети. Взгляд физиотерапевта В практику педиатра Recurrent respiratory infections in childhood. Physiotherapist’s view. 2012.
Sánchez-Solís M., García-Marcos L. Bronchopulmonary Dysplasia: The Importance Of Physical Exercise // Arch. Bronconeumol. SEPAR, 2019. Vol. 55, № 12. P. 609–610.
Meyer EC, Coll CT, Lester BM, Boukydis CF, McDonough SM O.W. Family-based intervention improves maternal psychological well-being and feeding interaction of preterm infants. // Pediatrics. 1994. Vol. 93, № 2. P. 241–246.
Brady J.M. et al. Living with Severe Bronchopulmonary Dysplasia—Parental Views of Their Child’s Quality of Life // J. Pediatr. Elsevier Inc., 2019. Vol. 207. P. 117–122.
Ischander M L.-S.S. Psychologist’s Unique Role in Improving Quality of Life of Children with Chronic Lung Diseases and Their Families. // Pediatr Clin North Am. 2022. Vol. 69, № 5. P. 951–963.
Gibbs K. et al. Ventilation Strategies in Severe Bronchopulmonary Dysplasia // Neoreviews. 2020. Vol. 21, № 4. P. e226–e237.
Oei J.L. et al. Higher or lower oxygen for delivery room resuscitation of preterm infants below 28 completed weeks gestation: A meta-analysis // Arch. Dis. Child. Fetal Neonatal Ed. BMJ Publishing Group, 2017. Vol. 102, № 1. P. F24–F30.
Foglia E.E., Jensen E.A., Kirpalani H. Delivery room interventions to prevent bronchopulmonary dysplasia in extremely preterm infants // J. Perinatol. 2017. Vol. 37, № 11. P. 1171–1179.
Saugstad O., Ramji S., Vento M. Resuscitation of depressed newborn infants with ambient air or pure oxygen: A meta-analysis // Biol. Neonate. 2005. Vol. 87, № 1. P. 27–34.
Oei J.L., Vento M. Is There a “Right” Amount of Oxygen for Preterm Infant Stabilization at Birth? // Front. Pediatr. 2019. Vol. 7, № September. P. 1–11.
Oei JL, Finer NN, Saugstad OD, Wright IM, Rabi Y, Tarnow-Mordi W, Rich W, Kapadia V, Rook D, Smyth JP, Lui K V.M. Outcomes of oxygen saturation targeting during delivery room stabilisation of preterm infants. // Arch Dis Child Fetal Neonatal Ed. 2018. Vol. 103, № 5. P. F446-F454.
Nobile S. et al. New Insights on Early Patterns of Respiratory Disease among Extremely Low Gestational Age Newborns // Neonatology. 2017. Vol. 112, № 1. P. 53–59.
Ho J., Subramaniam P., Davis P. Continuous positive airway pressure (CPAP) for respiratory distress in preterm infants // Cochrane Database Syst. Rev. 2020. Vol. 2020, № 10.
Subramaniam P., Ho J.J., Davis P.G. Prophylactic or very early initiation of continuous positive airway pressure (CPAP) for preterm infants // Cochrane Database Syst. Rev. 2021. Vol. 2021, № 10.
Ramaswamy V.V. et al. Efficacy of noninvasive respiratory support modes for primary respiratory support in preterm neonates with respiratory distress syndrome: Systematic review and network meta-analysis // Pediatr. Pulmonol. 2020. Vol. 55, № 11. P. 2940–2963.
Ramaswamy V.V. et al. Efficacy of noninvasive respiratory support modes as postextubation respiratory support in preterm neonates: A systematic review and network meta-analysis // Pediatr. Pulmonol. 2020. Vol. 55, № 11. P. 2924–2939.
Tanaka S. et al. New antibiotic regimen for preterm premature rupture of membrane reduces the incidence of bronchopulmonary dysplasia // J. Obstet. Gynaecol. Res. 2019. Vol. 45, № 5. P. 967–973.
Ramos-Navarro C. et al. Three-year perinatal outcomes of less invasive beractant administration in preterm infants with respiratory distress syndrome // J. Matern. Neonatal Med. 2020. Vol. 33, № 16. P. 2704–2710.
Härtel C. et al. Less invasive surfactant administration and complications of preterm birth // Sci. Rep. 2018. Vol. 8, № 1. P. 1–7.
Keszler M. Volume-Targeted ventilation: One size does not fit all. Evidence-based recommendations for successful use // Arch. Dis. Child. Fetal Neonatal Ed. 2019. Vol. 104, № 1. P. 108–112.
Dargaville P.A. et al. Incidence and outcome of CPAP failure in preterm infants // Pediatrics. 2016. Vol. 138, № 1.
Bahadue FL S.R. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. // Cochrane Database Syst Rev. 2012. Vol. 11, № 11. P. CD001456.
Виноградова И.В. , Виноградов Д.А. , Емельянова В.С. , Сейлиев А.А. , Волчков В.А. , Рындин А.Ю., Антонов А.Г. О.А.Р. Профилактика бронхолегочной дисплазии у новорожденных с низкой и экстремально низкой массой тела при рождении путем «позднего» введения сурфактанта // Российский вестник перинатологии и педиатрии. 2015. Vol. 60. P. 55–60.
Рындин А.Ю. Ионов О.В. Никитина И.В. Киртбая А.Р. Профилактика и лечение БЛД – сочетание методов малоинвазивного и ингаляционного введения сурфактантов // XI Всероссийский образовательный конгресс анестезия и реанимация в акушерстве и неонатологии 21-23 ноября 2018. 2018. P. 70–72.
Рындин Андрей Юрьевич. А.А.Г.. Способ профилактики бронхолегочной дисплазии у новорожденных с очень низкой и экстремально низкой массой тела при рождении. 2009. P. 1–16.
Herting E., Härtel C., Göpel W. Less invasive surfactant administration: best practices and unanswered questions // Curr. Opin. Pediatr. 2020. Vol. 32, № 2. P. 228–234.
Kribs A. et al. Nonintubated surfactant application vs conventional therapy in extremely preterm infants: A randomized clinical trial // JAMA Pediatr. 2015. Vol. 169, № 8. P. 723–730.
Isayama T., Chai-Adisaksopha C., McDonald S.D. Noninvasive ventilation with vs without early surfactant to prevent chronic lung disease in preterm infants: A systematic review and meta-analysis // JAMA Pediatr. 2015. Vol. 169, № 8. P. 731–739.
Aldana-Aguirre J.C. et al. Less invasive surfactant administration versus intubation for surfactant delivery in preterm infants with respiratory distress syndrome: A systematic review and meta-analysis // Arch. Dis. Child. Fetal Neonatal Ed. 2017. Vol. 102, № 1. P. F17–F23.
Abdel-Latif M.E. et al. Surfactant therapy via thin catheter in preterm infants with or at risk of respiratory distress syndrome // Cochrane Database Syst. Rev. 2021. Vol. 2021, № 5.
Kamlin C.O.F., Davis P.G. Long versus short inspiratory times in neonates receiving mechanical ventilation // Cochrane Database Syst. Rev. Wiley, 2003.
Kirpalani H. et al. Effect of Sustained Inflations vs Intermittent Positive Pressure Ventilation on Bronchopulmonary Dysplasia or Death among Extremely Preterm Infants: The SAIL Randomized Clinical Trial // JAMA - J. Am. Med. Assoc. 2019. Vol. 321, № 12. P. 1165–1175.
Berger J. et al. Impact of early extubation and reintubation on the incidence of bronchopulmonary dysplasia in neonates // Am. J. Perinatol. 2014. Vol. 31, № 12. P. 1063–1072.
Schmidt B. et al. Long-Term Effects of Caffeine Therapy for Apnea of Prematurity // N. Engl. J. Med. 2007. Vol. 357, № 19. P. 1893–1902.
Davis P.G. et al. Caffeine for Apnea of Prematurity Trial: Benefits May Vary in Subgroups // J. Pediatr. Mosby Inc., 2010. Vol. 156, № 3.
Elmowafi M. et al. Prophylactic versus therapeutic caffeine for apnea of prematurity: a randomized controlled trial // J. Matern. Neonatal Med. Taylor & Francis, 2022. Vol. 35, № 25. P. 6053–6061.
Sweet D.G. et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome: 2022 Update // Neonatology. 2023. Vol. 120, № 1. P. 3–23.
Barbara Schmidt et al. Caffeine therapy for apnea of prematurity // N Engl J Med. 2006. Vol. 354, № 20. P. 2112–2121.
Jensen E.A., Foglia E.E., Schmidt B. Evidence-Based Pharmacologic Therapies for Prevention of Bronchopulmonary Dysplasia: Application of the Grading of Recommendations Assessment, Development, and Evaluation Methodology // Clin. Perinatol. Elsevier Inc, 2015. Vol. 42, № 4. P. 755–779.
Lodha A. et al. Association of early caffeine administration and neonatal outcomes in very preterm neonates // JAMA Pediatr. 2015. Vol. 169, № 1. P. 33–38.
Lodha A. et al. Early caffeine administration and neurodevelopmental outcomes in preterm infants // Pediatrics. 2019. Vol. 143, № 1.
https://clinicaltrials.gov/ct2/show/NCT03086473?term=03086473&draw=2&rank=1 [Electronic resource].
Doyle L.W. et al. Late (≥ 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants // Cochrane Database Syst. Rev. 2021. Vol. 2021, № 11.
Muehlbacher T., Bassler D., Bryant M.B. Evidence for the management of bronchopulmonary dysplasia in very preterm infants // Children. 2021. Vol. 8, № 4.
Баранов А. А. , Намазова-Баранова Л. С. , Беляева И. А., Давыдова И.В. и др. Иммунопрофилактика инфекционных болезней у недоношенных детей // Педиатрическая фармакология. 2018. Vol. 15, № 5. P. 376–389.
Charles E. et al. Small for gestational age and extremely low birth weight infant outcomes // J. Perinat. Med. 2019. Vol. 47, № 2. P. 247–251.
Wang D., Bayliss S., Meads C. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses. // Health Technol. Assess. (Rockv). 2011. Vol. 15 5. P. iii–iv, 1–124.
Gonzales T. et al. Effectiveness and Safety of Palivizumab for the Prevention of Serious Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus: A Systematic Review // Am. J. Perinatol. 2022.
Baraldi E. et al. Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants // Ital. J. Pediatr. 2014. Vol. 40, № 1. P. 1–13.
Brady M.T. et al. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection // Pediatrics. 2014. Vol. 134, № 2. P. 415–420.
Andabaka T., Rojas-Reyes M.X. Cochrane in context: Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children // Evidence-Based Child Heal. 2013. Vol. 8, № 6. P. 2377–2379.
Информационное письмо: О рекомендуемых сроках проведения иммунопрофилактики респираторно-синцитиальной вирусной инфекции у детей из групп риска [электронный ресурс] [Electronic resource] // http://niidi.ru/news/informatsionnoe-pis-mo-o-rekomenduemykh-srokakh-provedeniya-immunoprofilaktiki-respiratorno-sintsitial-noy-virusnoy-infe/. 2023.
Thomas W., Speer C.P. Management of infants with bronchopulmonary dysplasia in Germany // Early Hum. Dev. 2005. Vol. 81, № 2. P. 155–163.
Brydak L.B. et al. Antibody response to influenza vaccine in children with bronchopulmonary dysplasia [2] // Infection. 2001. Vol. 29, № 3. P. 181–182.
Davidson L.M., Berkelhamer S.K. Bronchopulmonary dysplasia: Chronic lung disease of infancy and long-term pulmonary outcomes // J. Clin. Med. 2017. Vol. 6, № 1. P. 6–8.
Dionne J.M., Abitbol C.L., Flynn J.T. Hypertension in infancy: Diagnosis, management and outcome // Pediatr. Nephrol. 2012. Vol. 27, № 1. P. 17–32.
Hassan R V.R. Neonatal Hypertension. / ed. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing;, 2022.
Luyckx V.A. et al. A Developmental Approach to the Prevention of Hypertension and Kidney Disease – a report from the Birth Weight and Nephron Number Working Group // Lancet. 2017. Vol. 390, № 10092. P. 424–428.
Давыдова И.В., Аникин А.В., Кустова О.В., Сиденко А.В., Басаргина Е.Ю., Павлюкова Е.В. П.В.К. Бронхолегочная дисплазия в постсурфактантную эру: результаты объективной оценки течения заболевания // Вопросы современной педиатрии. 2015. Vol. 14, № 4. P. P. 514-518.